{
    "clinical_study": {
        "@rank": "144845", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global\n      severity and compulsive dimensions of children and adolescents with autism.\n\n      II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this\n      patient population.\n\n      III. Compare the baseline compulsive severity and treatment outcome in these patients."
        }, 
        "brief_title": "Randomized Study of Fluoxetine in Children and Adolescents With Autism", 
        "condition": "Autism", 
        "condition_browse": {
            "mesh_term": "Autistic Disorder"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study.\n      All patients receive oral placebo daily during week 0.\n\n      Patients are randomized to receive either oral fluoxetine or oral placebo daily on weeks\n      1-8.  Patients then crossover to receive treatment on the other arm during weeks 12-20."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Meets diagnostic criteria for autism\n\n        --Prior/Concurrent Therapy--\n\n        Other:\n\n          -  At least 3 months since prior electroconvulsive therapy\n\n          -  At least 1 month since prior investigational drugs or treatment with any drug known\n             to cause major organ toxicity\n\n          -  At least 2 weeks since prior monoamine oxidase inhibitors\n\n          -  At least 6 weeks since prior long acting phenothiazines\n\n          -  At least 1 week since prior other psychotropic drugs\n\n          -  No prior fluoxetine of 20 mg/day for 6 weeks\n\n          -  At least 6 weeks since prior fluoxetine\n\n          -  No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)\n\n          -  No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise\n             permitted)\n\n          -  Prior participation in another serotonin reuptake inhibitor trial allowed\n\n        --Patient Characteristics--\n\n        Hematopoietic: No significant hematopoietic disease\n\n        Hepatic: No prior or concurrent liver disease\n\n        Renal: No prior or concurrent kidney disease\n\n        Cardiovascular:\n\n          -  No significant cardiovascular disease\n\n          -  No abnormal EKG\n\n        Neurological:\n\n          -  No prior seizure disorder or high risk development of seizures\n\n          -  No prior cerebrovascular disease\n\n          -  No prior brain trauma\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  No unstable major medical illness or systemic disease\n\n          -  No moderate or severe mental retardation and motor deficits (IQ less than 50)\n\n          -  No family history of bipolar disorder\n\n          -  No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective,\n             organic, or bipolar disorders)\n\n          -  No significant autoaggressive behavior or serious suicidal risk\n\n          -  No prior or concurrent gastrointestinal conditions\n\n          -  No unstable endocrine disease (e.g., hypo or hyperthyroidism)\n\n          -  No prior or concurrent malignancy\n\n          -  Must be able to tolerate tapering of psychoactive medication\n\n          -  No history of hypersensitivity or severe side effects to fluoxetine or other\n             serotonin reuptake inhibitors\n\n          -  No history of severe personality disorder or noncompliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": "45", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004486", 
            "org_study_id": "199/14266", 
            "secondary_id": [
                "MTS-FDR001520", 
                "MTS-GCO-96-713"
            ]
        }, 
        "intervention": {
            "intervention_name": "fluoxetine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "keyword": [
            "autism", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "December 7, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Albert Einstein College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York University Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Eric Hollander", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004486"
        }, 
        "results_reference": {
            "PMID": "15602505", 
            "citation": "Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005 Mar;30(3):582-9."
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1998", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2000"
    }, 
    "geocoordinates": {
        "Albert Einstein College of Medicine": "40.85 -73.867", 
        "Mount Sinai School of Medicine": "40.714 -74.006", 
        "New York University Medical Center": "40.714 -74.006"
    }
}